RxDoctor Payments Data

Aneela Majeed

Internal Medicine · Tucson, AZNPI 1285898742

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Pharmacosmos Therapeutics Inc. at 24.9% of the total.

$710in general payments, 2019–2025

Across 6 payments — averaging $118.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$177
  • Beigene USA, Inc.$150
  • Johnson & Johnson$146
  • Takeda Pharmaceuticals U.S.A., Inc.$136
  • GSK$101
$74,856in research payments, 2019–2025

Across 29 payments — averaging $2581.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nobelpharma America, LLC$75K

What the payments were for

  • Food & beverage$710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$710 in reported general payments places this provider in the 70th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$51,731
Medicare patients
103
Services billed
468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErtapenemErtapenem Sodium16$9,269
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam11$3,233
Vancomycin Hcl14$1,079

Paid to pharmacies, not to this prescriber.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →